Evidence map›Paper›PMID 39002444›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2024

PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer.

Tayo Alex Adekiya, Tamaro Hudson, Oladapo Bakare, Edmund E Ameyaw, Amusa Adebayo, Oluwabukunmi Olajubutu, Simeon K Adesina

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tayo Alex AdekiyaDepartment of Pharmaceutical Sciences, Howard University, Washington, DC, USA.
Tamaro HudsonCancer Center, Howard University, Washington, DC 20059, USA.
Oladapo BakareDepartment of Chemistry, Howard University, Washington, DC, USA.
Edmund E AmeyawDepartment of Pharmaceutical Sciences, Howard University, Washington, DC, USA.
Amusa AdebayoDepartment of Pharmaceutical Sciences, Howard University, Washington, DC, USA.
Oluwabukunmi OlajubutuDepartment of Pharmaceutical Sciences, Howard University, Washington, DC, USA.
Simeon K AdesinaDepartment of Pharmaceutical Sciences, Howard University, Washington, DC, USA. Electronic address: simeon.adesina@howard.edu.

Funding

Stealth Brusatol and Docetaxel-loaded Nanoparticles for Targeted Prostate Cancer TherapySC1GM131982 · NIGMS · HOWARD UNIVERSITY · PI ADESINA, SIMEON KOLAWOLE · 2019 to 2021
$888k
NIGMS NIH HHS SC1 GM131982
6 · The paper itself

Abstract

Active targeting to cancer involves exploiting specific interactions between receptors on the surface of cancer cells and targeting moieties conjugated to the surface of vectors such that site-specific delivery is achieved. Prostate specific membrane antigen (PSMA) has proved to be an excellent target for active targeting to prostate cancer. We report the synthesis and use of a PSMA-specific ligand (Glu-NH-CO-NH-Lys) for the site-specific delivery of brusatol- and docetaxel-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles to prostate cancer. The PSMA targeting ligand covalently linked to PLGA-PEG

Indexed as

Antigens, SurfaceDocetaxelGlutamate Carboxypeptidase IINanoparticlesProstatic NeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorHumansMaleMiceMice, Inbred BALB CMice, NudeNanoparticle Drug Delivery SystemPC-3 CellsReactive Oxygen SpeciesAntigens, SurfaceAntineoplastic AgentsDocetaxelFOLH1 protein, humanGlutamate Carboxypeptidase IINanoparticle Drug Delivery SystemReactive Oxygen SpeciesCombination therapyDrug targetingNanoparticlesProstate specific membrane antigenReactive oxygen species

Identifiers

PMID39002444
PMCPMC11384235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.